BIOCARDIA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3766 USD | +2.34% |
|
+4.61% | -43.30% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.
Calendar
2024-04-30
- Business Update Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3766
USD
Average target price
4
USD
Spread / Average Target
+962.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.30% | 10.12M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BCDA Stock
- News BioCardia, Inc.
- Sector Update: Health Care Stocks Advancing in Afternoon Trading
